top of page
lurm-358339-unsplash.jpg

Ombeline Degreze-Péchade

Partner

​

Lawyer registered at the Paris Bar

​

odp@schertenleib-avocats.com

  • LinkedIn - Black Circle

Ombeline began her university studies at the Faculty of Medicine and Pharmacy in Limoges (Haute-Vienne). This initial training, with its rigorous selection process, gave her a scientific background in chemistry, biology and physics.

 

Ombeline then turned to law studies, which she validated with a Master II in health law and a Master II in private law, respectively obtained at the Faculty of Law of Poitiers (Vienne) and the Faculty of Law of Paris I - La Sorbonne, before becoming a lawyer and registering at the Paris Bar in 2010.

 

In line with her dual training and the experience she has gained through her advisory and litigation work, in which she has represented several leading French and international laboratories and companies, Ombeline has specialised in

 

  • patent law and civil litigation, in the pharmaceutical field (for generic laboratories but also for innovative laboratories in cases concerning molecules derived from biotechnology), medical devices, but also in other technologies (telecommunications and mechanics in particular);

 

 

  • pharmaceutical law in all its regulatory aspects,

 

  • product liability law (in all areas of industry: cosmetics, pharmaceuticals, food processing, mechanical engineering).

 

In addition to French, which is her mother tongue, Ombeline is fluent in English.

Education​

​

Master II (DESS) Health Law, University of Poitiers

 

Master II General Private Law, University of Paris I Panthéon La Sorbonne

​

​

​

Affiliation 

​

LES, AIPPI

Réseau

​

BioLaw Europe

What others say

​

"Ombeline Degrèze-Péchade has a great knowledge of medical and biological subjects." Legal 500 2022

Significant public cases

  • Represented a generic company in the defence of a patent infringement action relating to a urea aryl compound used in the treatment of human cancers;

  • Represented a generic company in an action for invalidation of a patent relating to the treatment of thromboembolic disorders;

  • Represented a generic company in an infringement action brought by an originator company on the basis of a SPC combining sitagliptin with metformin for the treatment of diabetes;

  • Represented a major player in aesthetic medicine in a dispute concerning know-how (claims of more than 150 million euros) and two patents relating to a process for manufacturing hyaluronic acid fillers;

  • Represented a company specialising in the manufacture of electronic products and mobile phones against a telecommunications company in a contractual action aimed at obtaining a FRAND licence;

  • Represented a generic laboratory in defence of patent infringement litigation relating to a cytostatic anti-cancer agent;

  • Represented a laboratory manufacturing diagnostic medical devices in an arbitration;

  • Represented a generic company in a patent invalidity action relating to analogues of gaba and L-glutamic acid for the treatment of central nervous system diseases;

  • Represented a generic company in a patent infringement action relating to zidovudine combinations for the treatment of HIV;

  • Represented an originator company in a patent infringement action relating to a monoclonal antibody used in the treatment of diabetes;

  • Represented an innovator company against an originator company in an action for invalidation of two patents relating to the prevention and treatment of amyloidogenic diseases;

  • Represented a generic laboratory in an infringement action brought by an originator laboratory on a patent relating to a molecule allowing the preparation of a pharmaceutical composition to treat pain;

  • Represented a company specialising in 3D cinema technology in a patent infringement action relating to polarisation conversion systems for stereoscopic projection;

  • Represented a generic laboratory in an action for invalidation of a patent relating to a dibenzothiazepine derivative protecting a sustained release formulation and its use in the treatment of psychotic states in humans;

  • Represented a medical device company in a patent infringement action relating to a method of diagnosing sepsis;

  • Represented a generic company in an action for invalidation of an SPC relating to the combination of tenofovir disoproxil and its salts, hydrates, tautomers and solvates in combination with other therapeutic compounds in the treatment of HIV;

  • Represented a generic company in an action to invalidate an SPC for a combination of efavirenz, emtricitabine and tenofovir in the treatment of HIV;

  • Represented a laboratory manufacturing diagnostic medical devices in a civil liability action for the alleged defectiveness of its diagnostic tests for Lyme disease;

  • Represented a generic company in an action for invalidity of a SPC for the combination of ezetimibe and simvastatin;

  • Represented a generic company in a dispute before the administrative court concerning the marketing authorisation of a drug based on bendamustine hydrochloride;

  • Represented a generic company against an originator company in an action for infringement and unfair competition of three patents relating to an anti-estrogen effective in the treatment of breast cancer;

  • Represented a generic company in the defence of an action for interim injunction brought by an originator company in respect of a SPC relating to darunavir, a treatment for HIV;

  • Represented a generic company in the defence of summary proceedings and on the merits of infringement proceedings brought by an originator company on the basis of a SPC relating to a combination of ezetimibe and simvastatin in an anticholesterol treatment;

  • Represented a pharmaceutical and medical device consulting company against a French laboratory in a contractual liability action;

  • Represented a generic company in an infringement action brought by an originator company against a patent relating to the combination of pemetrexed and 

bottom of page